WO2025002221 - MULTI-SPECIFIC ANTIBODIES COMPRISING ANTIGEN-BINDING DOMAINS SPECIFICALLY RECOGNIZING C5AR1 AND GM-CSFR ALPHA
National phase entry:
Publication Number
WO/2025/002221
Publication Date
02.01.2025
International Application No.
PCT/CN2024/101864
International Filing Date
27.06.2024
Title **
[English]
MULTI-SPECIFIC ANTIBODIES COMPRISING ANTIGEN-BINDING DOMAINS SPECIFICALLY RECOGNIZING C5AR1 AND GM-CSFR ALPHA
[French]
ANTICORPS MULTI-SPÉCIFIQUES COMPRENANT DES DOMAINES DE LIAISON À L'ANTIGÈNE RECONNAISSANT DE MANIÈRE SPÉCIFIQUE C5AR1 ET GM-CSFR ALPHA
Applicants **
STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.
No.36, Jinghai Er Road, Beijing Economic-Technological Development Area
Daxing District, Beijing 100176, CN
Inventors
HE, Chong
No.36, Jinghai Er Road, Beijing Economic-Technological Development Area
Daxing District, Beijing 100176, CN
ZHAI, Wenwu
No.36, Jinghai Er Road, Beijing Economic-Technological Development Area
Daxing District, Beijing 100176, CN
ZHOU, Zhiwen
No.36, Jinghai Er Road, Beijing Economic-Technological Development Area
Daxing District, Beijing 100176, CN
STRAINIC, Michael George
2600 Hilltop Drive Richmond
California, US
YUAN, Ping
2600 Hilltop Drive Richmond
California, US
YI, Zuoan
2600 Hilltop Drive Richmond
California, US
Priority Data
PCT/CN2023/102813
27.06.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3012 | |
| EPO | Filing, Examination | 16443 | |
| Japan | Filing | 587 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 8260 |
Total: 28876 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provides multi-specific (e.g., bispecific) antibodies that specifically recognize C5aR1 and GM-CSFRα, and pharmaceutical compositions comprising multi-specific (e.g., bispecific) antibodies that specifically recognize C5aR1 and GM-CSFRα. Also provided are methods of making and using these antibodies.[French]
L'invention concerne des anticorps multispécifiques (par exemple, bispécifiques) qui reconnaissent de manière spécifique C5aR1 et GM-CSFRα, et des compositions pharmaceutiques comprenant des anticorps multispécifiques (par exemple, bispécifiques) qui reconnaissent de manière spécifique C5aR1 et GM-CSFRα. L'invention concerne également des procédés de fabrication et d'utilisation de ces anticorps.